Skip to nav Skip to content
Mintallah  Haider

Mintallah Haider, MD

4.9 (334)

Specialty: Medical Oncology

Program: Gastrointestinal Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Adrenal Carcinoma, Adrenal Nodule/Mass, Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Neuroendocrine Tumor

    Dr. Haider is an Associate Member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center and an Associate Professor of Oncologic Sciences at University of South Florida. Dr. Haider received her Bachelor of Science as well as her Medical Degree at the University of Florida in Gainesville, FL. She completed an internship and residency in Internal Medicine at the University of Southern California in Los Angeles, CA followed by Hematology and Medical Oncology Fellowship at Moffitt Cancer Center – University of South Florida in Tampa, FL. Dr. Haider’s clinical practice is focused on neuroendocrine tumor (NET) oncology. As a member of the Endocrine Program Multidisciplinary team, she also treats paraganglioma and pheochromocytoma. In parallel, Dr. Haider leads and participates in clinical research focused on the systemic therapies of these tumors. As a Clinical Educator, she participates in the education of medical students, residents and fellows as well as community outreach. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), where she serves on the Continuing Education Committee and has been an invited moderator and speaker at NANETS national and regional seminars. Dr. Haider shares her expertise as a speaker at community medical societies as well as patient educational groups. She serves patients at Moffitt Cancer Center - Magnolia and Moffitt International Plaza.

    Education & Training


    • University of South Florida - Hematology and Medical Oncology


    • University of Southern California - Internal Medicine

    Medical School:

    • University of Florida College of Medicine - MD
  • Participating Trials

    Clinical Trial 21790
    Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
    Condition: Gastrointestinal Tumor
    Intervention: Atezolizumab (Tecentriq); Etoposide (); Paraplatin (carboplatin); carboplatin (); cisplatin (); etoposide ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Laber DA, Patel PC, Logothetis CN, Patel AK, Jaglal M, Haider M, Visweshwar N, Rajasekaran-Rathnakumar G, Eatrides J. Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study. Eur J Haematol. 2024 Mar.112(3):450-457. Pubmedid: 37984551.
    • Al-Toubah T, Schell MJ, Morse B, Haider M, Valone T, Strosberg J. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. ESMO Open. 2024 Apr.9(4):102386. Pubmedid: 38507897. Pmcid: PMC10966166.
    • Al-Toubah T, Pelle E, Hallanger-Johnson J, Haider M, Strosberg J. ACTH-secreting pancreatic neuroendocrine neoplasms: A case-series. J Neuroendocrinol. 2023 Oct.35(10):e13336. Pubmedid: 37688510.
    • Stokes SM, Haider M, Vadaparampil ST, Levitt C, Hardy O, Kim R, Castillo DL, Denbo J, Fleming JB, Anaya DA. Patient's informational needs and outreach preferences: A cross-sectional survey study in patients with hepatobiliary malignancies. PEC Innov. 2023 Dec.4:100248. Pubmedid: 38292078. Pmcid: PMC10825679.
    • Al-Toubah T, Montilla-Soler J, El-Haddad G, Haider M, Strosberg J. Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans. J Nucl Med. 2023 Dec.64(12):1895-1898. Pubmedid: 37797976.
    • Saller JJ, Haider M, Al-Diffalha S, Coppola D. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin. Anticancer Res. 2022 Mar.42(3):1381-1396. Pubmedid: 35220231.
    • Sinnamon AJ, Wood AC, Satyadi MA, Levitt CV, Hardy O, Haider M, Kim RD, Anaya DA, Denbo JW. Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter?. J Gastrointest Oncol. 2022 Jun.13(3):1413-1422. Pubmedid: 35837169. Pmcid: PMC9274032.
    • Ehab J, Powers B, Kim R, Haider M, Utuama O, Chin A, Denbo J, Kis B, Frakes J, Jeong D, Lauwers G, Vadaparampil S, Fleming JB, Anaya DA. ASO Visual Abstract: Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients with Liver Malignancies. Ann Surg Oncol. 2022 Apr.29(4):2381-2382. Pubmedid: 34716839.
    • Ehab J, Powers B, Kim R, Haider M, Utuama O, Chin A, Denbo J, Kis B, Frakes J, Jeong D, Lauwers G, Vadaparampil S, Fleming JB, Anaya DA. Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients With Liver Malignancies. Ann Surg Oncol. 2022 Apr.29(4):2371-2380. Pubmedid: 34671878.
    • Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer. 2021 Mar.28(3):R81-R93. Pubmedid: 33608483. Pmcid: PMC8118168.
    • Logothetis CN, Patel A, Eatrides J, Jaglal M, Haider M, Visweshwar N, Laber DA. Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution. J Clin Med. 2021 Jul.10(15). Pubmedid: 34362201. Pmcid: PMC8347784.
    • Anaya DA, Dogra P, Wang Z, Haider M, Ehab J, Jeong DK, Ghayouri M, Lauwers GY, Thomas K, Kim R, Butner JD, Nizzero S, Ramírez JR, Plodinec M, Sidman RL, Cavenee WK, Pasqualini R, Arap W, Fleming JB, Cristini V. A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases. Cancers (Basel). 2021 Jan.13(3). Pubmedid: 33503971. Pmcid: PMC7866038.
    • Strosberg JR, Al-Toubah T, Pellè E, Smith J, Haider M, Hutchinson T, Fleming JB, El-Haddad G. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. J Nucl Med. 2021 Jan.62(1):69-72. Pubmedid: 32444368.
    • Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms. J Natl Compr Canc Ne. 2021 Aug.20(1):29-36. Pubmedid: 34433130.
    • Laber DA, Eatrides J, Jaglal MV, Haider M, Visweshwar N, Patel A. A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer. Med Oncol. 2020 Sep.37(10):95. Pubmedid: 32979106.
    • Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, Padron E, Komrokji RS. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 Jun.20(6):400-406.e2. Pubmedid: 32179032. Pmcid: PMC7771378.
    • Al-Toubah T, Strosberg J, Halfdanarson T, Oleinikov K, Gross DJ, Haider M, Sonbol MB, Almquist D, Grozinsky-Glasberg S. Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. Chest. 2020 Jul.158(1):401-405. Pubmedid: 32059961.
    • Haider M, Al-Toubah T, El-Haddad G, Strosberg J. Molecular imaging and radionuclide therapy of neuroendocrine tumors. Curr Opin Endocrinol Diabetes Obes. 2020 Feb.27(1):16-21. Pubmedid: 31789833.
    • Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2017 Dec.37:480-494. Pubmedid: 28561687.
    • Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S44-S48. Pubmedid: 27521323.
    • Aldoss I, Ji L, Haider M, Pullarkat V. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia. Acta Haematol. 2014 Jul.131(4):202-207. Pubmedid: 24296475.
    • Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012 Apr.78(14):1096-1099. Pubmedid: 22474298.
    • Tzachanis D, Haider M, Papazisis G. A Case of Subacute Encephalopathy Developing After Treatment With Clofarabine and Methotrexate That Resolved With Corticosteroids. Am J Ther. 23(3):e937-e940. Pubmedid: 24987945.
  • Patient Comments

    Overall Satisfaction


    334 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor